Angiomyolipoma pathophysiology: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 30: | Line 30: | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Needs overview]] | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} |
Revision as of 14:28, 7 March 2013
Angiomyolipoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Angiomyolipoma pathophysiology On the Web |
American Roentgen Ray Society Images of Angiomyolipoma pathophysiology |
Risk calculators and risk factors for Angiomyolipoma pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Pathophysiology
Since all three components of an angiomyolipoma (vascular cells, immature smooth muscle cells and fat cells) contain a "second hit" mutation, they are believed to have derived from a common progenitor cell that suffered the common second hit mutation.[1]
Microscopic Pathology